Αρχική World News A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose... World News A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer Από Ogkologos - 21 Νοεμβρίου, 2025 458 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR New Safety Signal for Use of Ibrutinib in Combination with Rituximab... 15 Σεπτεμβρίου, 2021 After Struggling With Chronic Illnesses Most of Her Life, This Author... 21 Ιουνίου, 2021 New Blood Test Can Screen For Over 50 Cancers 7 Ιουνίου, 2021 FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC 5 Φεβρουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Facing the future: “How can a 3-year old understand that her... Home Is Where the Heart Is Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma 15% of People With Lung Cancer Have an Inherited Mutation for...